FDC Ltd reported 5.92% growth in total revenues for the Dec-20 quarter on consolidated basis at Rs340.23cr. During the second half of the year, FDC completed consolidating the operations of Fair Deal Pharma of South Africa to establish its foothold in the African region in a more conclusive manner.
The consolidated Profit after tax (PAT) for the Dec-20 quarter was up 1.43% at Rs75.21cr. Like most pharma companies, FDC also faced a sharp spike in its raw material costs as the supply chain constraints stoked prices and put pressure on profit growth. As a result, the PAT margins actually tapered from 23.08% in Dec-19 to 22.11% in Dec-20.
Financial highlights for Dec-20 compared yoy and sequentially
|
|
FDC Ltd |
|
|
|
|
|
Rs in Crore |
Dec-20 |
Dec-19 |
YOY |
Sep-20 |
QOQ |
|
Total Income (Rs cr) |
₹ 340.23 |
₹ 321.22 |
5.92% |
₹ 371.39 |
-8.39% |
|
Net Profit (Rs cr) |
₹ 75.21 |
₹ 74.15 |
1.43% |
₹ 88.08 |
-14.61% |
|
|
|
|
|
|
|
|
Diluted EPS (Rs) |
₹ 4.45 |
₹ 4.31 |
|
₹ 5.15 |
|
|
Net Margins |
22.11% |
23.08% |
|
23.72% |
|
Related Tags: